Microbot Medical Inc. (NASDAQ:MBOT) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Microbot Medical Inc. (NASDAQ:MBOT) have received an average rating of “Moderate Buy” from the five analysts that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, two have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $7.50.

A number of analysts have commented on MBOT shares. HC Wainwright reiterated a “buy” rating and issued a $12.00 price objective on shares of Microbot Medical in a research report on Friday, November 28th. Roth Mkm initiated coverage on shares of Microbot Medical in a research report on Wednesday, December 3rd. They set a “buy” rating and a $5.50 target price on the stock. Finally, B. Riley Financial assumed coverage on shares of Microbot Medical in a research report on Tuesday, February 10th. They issued a “buy” rating for the company.

Institutional Trading of Microbot Medical

Large investors have recently bought and sold shares of the stock. DNB Asset Management AS increased its holdings in shares of Microbot Medical by 67.9% during the second quarter. DNB Asset Management AS now owns 192,786 shares of the biotechnology company’s stock worth $486,000 after buying an additional 77,965 shares in the last quarter. CIBC Private Wealth Group LLC lifted its position in Microbot Medical by 137.6% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,454,000 shares of the biotechnology company’s stock worth $4,435,000 after buying an additional 842,000 shares in the last quarter. Heights Capital Management Inc. acquired a new position in Microbot Medical during the 3rd quarter worth about $2,693,000. Zacks Investment Management bought a new stake in Microbot Medical during the 3rd quarter worth about $33,000. Finally, EHP Funds Inc. acquired a new stake in Microbot Medical in the 3rd quarter valued at about $78,000. 16.30% of the stock is currently owned by institutional investors.

Microbot Medical Price Performance

Shares of Microbot Medical stock opened at $2.38 on Friday. The firm has a fifty day moving average price of $2.10 and a two-hundred day moving average price of $2.54. Microbot Medical has a fifty-two week low of $1.34 and a fifty-two week high of $4.67. The company has a market cap of $159.84 million, a PE ratio of -5.29 and a beta of 1.22.

Microbot Medical Company Profile

Microbot Medical Inc (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.